Drug Profile
Golexanolone - Umecrine Cognition
Alternative Names: GR-3027Latest Information Update: 17 Aug 2023
Price :
$50
*
At a glance
- Originator Umecrine Cognition
- Class Alkynes; Androstanes; Hepatoprotectants; Imines; Neuroprotectants; Small molecules
- Mechanism of Action GABA-A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatic encephalopathy
- Phase I/II Primary biliary cirrhosis
- Preclinical Parkinson's disease
- No development reported Idiopathic hypersomnia
Most Recent Events
- 21 Jun 2023 Pharmacodynamics data from preclinical trials in Primary biliary cirrhosis presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)
- 27 Mar 2023 Phase-II clinical trials in Hepatic encephalopathy (PO) (Umecrine Cognition pipeline, March 2023)
- 17 Jan 2023 Golexanolone receives Orphan Drug status for Primary biliary cirrhosis in USA